The effect of the 3- (2-phenylethyl) -2-thioxo-1,3-thiazolidin-4-one clathrate complex with betadex on protein metabolism, growth and development of Wistar

The clathrate complex of 3- (2-phenylethyl) -2-thioxo-1,3 thiazolidin-4-one with betadex was developed for the first time. 1: 5 ratio obtained by the solid-phase synthesis method, which has a crystalline form in the form of nanoparticles with an average size of 40.5 nm. In the present work, the effect of the created nanoscale form of 3- (2-phenylethyl) -2-thioxo-1,3 thiazolidin-4-one on protein metabolism, growth and development of Wistar rats was first studied. It was shown that the administration of 3- (2-phenylethyl) -2-thioxo-1,3 thiazolidin-4-one nanosized form in rats at doses of 10.0 and 20.0 mg / kg body weight activates the biosynthetic system and promotes an increase in protein deposition in their body. Nitrogen retention in rats of the experimental groups compared with the control increased by 20.0% (P≤0.05) due to a decrease in its endogenous losses, and the urea content in the blood serum was lower by 24.1 and 26.4%, respectively, compared to control. In rats of the experimental groups, the concentration of total protein (P≤0.05), albumin (P≤0.05) and globulins in the blood was higher compared to the control. It was found that in female rats of the experimental groups, in comparison with the control and intact animals, their growth and development were statistically significantly higher. In this case, the optimal dose of the nanoscale form of 3- (2 – phenylethyl) -2-thioxo-1,3 thiazolidin-4-one is a dose of 10.0 mg / kg of rat body weight.

1. European Convention "On the Protection of Vertebrate Animals Used for Experiments or for Other Scientific Purposes" (ETS N 123) of March 18, 1986 - access mode: https://www.ru/abro/11036 (accessed 15.03. 2017).

2. Zhavoronkov L.P. Fundamentals of applied biomedical statistics. Toolkit. Obninsk: FSBI MRRC of the Ministry of Health and Social Development of Russia, 2012. 60 p.

3. Zemlyanoy R.A. The creation of a clathrate complex of β-cyclodextrin with a derivative of thiocyanate / Zemlyanoy R.A., Erimbetov K.T., Bondarenko E.V., Goncharova A.Ya., Frog E.S. // Experimental and clinical pharmacology. 2018.Vol. 81. P. 91.

4. Kondrasheva I.G., Bondarenko E.V., Erimbetov K.T., Kalashnikova E.E., Goncharova A.Ya. / Study of the antitumor activity of the original PAM-14 throat derivative on the Lewis lung carcinoma model // Abstracts of Sechenov International Biomedical Summit 2017 (SMBS-2017), June 16-20, 2017, Moscow. M .: Publishing house FSAEI HE First MGMU them. THEM. Sechenova of the Ministry of Health of Russia, 2017.-106 p. - P. 69-70.

5. Roziev R.A., Goncharova A.Ya., Erimbetov K.T., Podgorodnichenko V.K., Khomichenok V.V., Novozhilova N.E. Derivative of Rodanin and a tool for the prevention of tumor diseases // Patent for the invention of the Russian Federation No. 2521390. Published on June 27, 2014 Bull. Number 18.

6. Roziev R.A., Goncharova A.Ya., Erimbetov K.T., Podgorodnichenko V.K., Khomichenok V.V. An agent with antiproliferative and antimetastatic action for the treatment of tumor diseases // Patent for the invention of the Russian Federation No. 2522449. Published on July 10, 2014 Bull. Number 19.

7. Rosly IM, Vodolazhskaya MG Comparative approaches in assessing the condition of humans and animals: 1. cytolytic syndrome or fundamental mechanism // Journal of Veterinary Medicine - 2007, No. 43. - P. 63-66.

8. Coulambe S.S., Favreon G. New the semimicro method determination of urea // Clin. Chem. – 1963. – Vol. 1. – № 9. – P. 23-26.

9. Erimbetov K.T. Phenotypic regulation of animal skeletal muscle protein metabolism / Erimbetov K.T., Obvintseva O.V., Fedorova A.V., Zemlyanoy R.A., Solovieva A.G. // Ukrainian Journal of Ecology. – 2019. - Т. 9. - № 4. – С. 651-656.

10. Martinez A., Alonso M., Castro A., Dorronsoro I., Gelpí J. L., Luque F. J., Pérez C., Moreno F. J. (2005). SAR and 3D-QSAR Studies on Thiadiazolidinone Derivatives: Exploration of Structural Requirements for Glycogen Synthase Kinase 3 Inhibitors. J Med Chem, 48, 7103-7112.

11. Martinez A., Alonso M., Castro A., Pérez C., Moreno F. J. (2002). First Non-ATP Competitive Glycogen Synthase Kinase 3 â (GSK-3â) Inhibitors:Thiadiazolidinones (TDZD) as Potential Drugs for the Treatment of Alzheimer’s. J Med Chem, 45, 1292-1299.

12. Ravinder Singh Bhatti. Recent Pharmacological Developments on Rhodanines and 2,4-Thiazolidinediones / Ravinder Singh Bhatti, Sakshi Shah, Suresh, Pawan Krishan, Jagir S. Sandhu //Int. J. Med. Chem.-2013.-Vol 2013. Article ID 793260 – 16 pages. http://dx.doi.org/10.1155/2013/793260.